fbpx

molecules of the month

July 2022

An oral, brain penetrant EGFR mutant inhibitor with exquisite selectivity, a drug that was originally developed from a brain cholesterol metabolite, and a muscarinic antagonist and β2 agonist that was developed using soft drug design are some examples of this month's MOTM.

In the slide deck, you'll also find a drug utilizing an N-oxide motif and a drug optimized to overcome aldehyde oxidase metabolism.

Check out the ten molecule minireviews in the slide deck which covers:

  • Where are all of the Molecules of the Month in clinical development?
  • What's known about differentiation from previous molecules?
  • Where did the starting points come from?
  • Industry context, mechanism of action details, and more…

Join the Drug Hunter mailing list

to get free content and resources weekly. Trusted by > 5,500 drug hunters worldwide. Unsubscribe anytime.

This field is for validation purposes and should be left unchanged.
Newsletter

nominate a molecule

Encountered an interesting new molecule? Let your community know!

become a reviewer

Get sneak previews of upcoming molecules and share your knowledge and expertise with the drug discovery community.

Molecules

Join the Drug Hunter mailing list

to get free content and resources weekly. Trusted by > 5,500 drug hunters worldwide. Unsubscribe anytime.

This field is for validation purposes and should be left unchanged.
Newsletter

Join Subscribers from

…and hundreds more!